dr. Kim Van der Eecken (MD)
Despite recent therapeutic advances, metastatic hormone-sensitive prostate cancer (mHSPC) remains invariably fatal with varied outcomes across patients. Understanding its underlying biology is seen as a critical need to improve risk stratification and therapy selection.
In our research, we aim to study the molecular landscape of mHSPC through the analysis of tumor tissue and circulating tumor DNA. Ultimately, this research aims to improve precision clinical care among men with mHSPC.
- 2018-present: Pathologist in training, Ghent University.
- 2018-present: PhD fellow, Ghent University.
- 2018: Master of Medicine, Magna cum laude. Ghent University.
- 2011-2014: Bachelor of Medicine, Summa cum laude. Ghent University.
- Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer : a systematic review. European Urology Oncology, 2021, PMID: 34801437
- Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma. Genome Med, PMID: 32317009
- The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, PMID: 33419682
- Comparative analysis of somatic variant calling on matched FF and FFPE WGS samples. BMC Med Genomics, PMID: 32631411